MetaCap

Omeros (OMER) vs Savara (SVRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Omeros (OMER) has outperformed Savara (SVRA) over the past year, gaining 48.9% versus a loss of 13.4%. Over five years, SVRA leads with a +270.4% price change compared with +77.8% for OMER. Omeros is the larger company by market cap ($983.7 million vs $939.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OMER+48.93%SVRA-13.41%
+145%+62%-22%
Nov 21, 20251 yearNov 20, 2026
OMER+67.64%SVRA+294.44%
+572%+227%-118%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OMER versus SVRA key metrics
MetricOMERSVRA
Share price$13.21$4.26
Market cap$983.66M$939.86M
1-day change-5.71%-18.23%
YTD return-23.11%-29.35%
1-year return+48.93%-13.41%
5-year return+77.79%+270.43%
P/E ratio (TTM)15.92—
Forward P/E11.95—
EPS (TTM)$0.83$-0.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-3.35M$-118.84M
52-week high$21.24$7.01
52-week low$6.70$4.00
Distance from 52-week high-37.81%-39.19%
Analyst consensusbuystrong_buy
Avg. price target upside+108.18%+159.62%
Average volume1.36M2.79M
Shares outstanding74.46M220.62M
Employees17570
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OMER has outperformed SVRA by 62.3 percentage points over the past year.

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

About Savara

SVRA stock →

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

OMER vs SVRA FAQ

Which is bigger, Omeros or Savara?

Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $939.86M for Savara (SVRA).

Which stock has performed better over the past year, OMER or SVRA?

OMER returned +48.93% over the past 12 months, compared with -13.41% for SVRA (price return, excluding dividends). Past performance does not predict future results.

Are Omeros and Savara in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons